Meeting
2013 ASCO Annual Meeting
Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).
Authors
Kelly S. Oliner
Amgen, Inc., Thousand Oaks, CA
Kelly S. Oliner , Jean-Yves Douillard , Salvatore Siena , Josep Tabernero , Ronald L. Burkes , Mario Edmundo Barugel , Yves Humblet , Gyorgy Bodoky , David Cunningham , Jacek Jassem , Ilona Kocáková , Paul Ruff , Maria Blasinska-Morawiec , Martin Smakal , Richard Thomas Williams , Alan Rong , Jeffrey S. Wiezorek , Roger Sidhu , Scott D. Patterson , Fernando Rivera
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00364013
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3511)
DOI
10.1200/jco.2013.31.15_suppl.3511
Abstract #
3511
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild‑type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).
First Author: Lee Steven Schwartzberg
Poster
2016 ASCO Annual Meeting
Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
First Author: Tae Won Kim
Poster
2015 Gastrointestinal Cancers Symposium
Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).
First Author: Ann-Lii Cheng
Poster
2014 Gastrointestinal Cancers Symposium
FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC).
First Author: Thomas Brodowicz